

Capital Markets Presentation

Drägerwerk AG & Co. KGaA

April 2026, Lübeck

Disclaimer

This presentation does not constitute an offer of securities for sale or a solicitation of an offer to purchase any securities. No money, securities or other consideration is being solicited by this presentation.

This presentation contains forward-looking statements regarding the future development of the Dräger Group. These forward-looking statements are based on the current expectations, presumptions, and forecasts of the Executive Board as well as the information available to it to date, and have been made to the best of its knowledge and belief. No guarantee or liability for the occurrence of the future developments and results specified can be assumed in respect of such forward-looking statements. Rather, the future developments and results are dependent on a number of factors; they entail risks and uncertainties beyond our control and are based on assumptions which could prove to be incorrect. Notwithstanding any legal requirements to adjust forecasts, we assume no obligation to update the forward-looking statements contained in this presentation.

Interim financial reports and preliminaries are not audited.

Content – Agenda

01 Company

02 Financials

03 Outlook



**„Dräger products protect,
support and save lifes.“**


Stefan Dräger, Chairman of the Executive Board

01

—

Company

Net sales development – Long-term growth





Dräger worldwide

Net sales, employees, sites



- Headquarters
- Development and production sites
- Logistic centers
- Sales and service organizations



- Germany
- Europe, Middle East, and Africa (EMEA)
- Americas
- Asia-Pacific (APAC)

¹As of December 31, 2025, rounding differences in percentages

Our markets

Medical Technology



Hospital

Safety Technology



Fire Services



Oil and gas industry



Mining




Chemical industry









Other markets

Medical division



Note: Market positions based on Dräger's market knowledge and its own assessment of market position; positions ranked according to net sales.

Safety division

	Fire Service	Oil & Gas	Chemical	Mining	Other Markets
Breathing Systems  <ul style="list-style-type: none"> • Self-contained Breathing Apparatus for fire fighters • #2 worldwide and #1 in Europe 	✓	✓	✓	✓	✓
					✓
Gas Detection Systems  <ul style="list-style-type: none"> • Fixed and mobile gas detection systems • #1 worldwide and #1 in Europe 	✓	✓	✓	✓	✓
	✓	✓	✓	✓	✓
Personal Protection Equipment  <ul style="list-style-type: none"> • Protection equipment for hazardous working environments • Body and Head protection, rescue and escape devices, Masks and Filters, etc. 	✓	✓	✓	✓	✓
	✓	✓	✓	✓	✓
Impairment Check Equipment  <ul style="list-style-type: none"> • Alcohol- and drug screening devices • Interlock devices • #1 worldwide and #1 in Europe 					
Engineered Solutions  <ul style="list-style-type: none"> • Customer specific solutions • mobile and stationary firefighting training systems • Rescue chambers 					
Service & Consumables  <ul style="list-style-type: none"> • Spareparts and consumables • Product Service • Rental, On-site shops and Shutdown Service • Marine-Offshore Service 					

Note: Market positions based on Dräger's market knowledge and its own assessment of market position; positions ranked according to net sales.

Medical and safety technology providing long-term growth prospects

	Medical division	Safety division
Attractive growth prospects in sizeable markets ...	<ul style="list-style-type: none"> • Average expected annual market growth for the global medical equipment market significantly exceeding growth in many other sectors • Strong growth prospects in both developed and emerging markets 	<ul style="list-style-type: none"> • Very diversified markets with numerous product and service offerings • Attractive growth prospects for target sectors (e.g. industry) and growing safety investments
... in developed markets ...	<ul style="list-style-type: none"> • Rapidly aging population and consequently increasing healthcare expenditure • Increasing demand for medical equipment to improve clinical workflows and efficiency 	<ul style="list-style-type: none"> • Increasingly stricter safety regulations • Rising environmental awareness • Improved outlook for target markets
... as well as in emerging markets.	<ul style="list-style-type: none"> • Strong growth of GDP and population resulting in a demand for improved medical services • Political benefits from investments in health care sector 	<ul style="list-style-type: none"> • Increasingly higher safety standards • Increasing industrial hygiene awareness • Strong growth of key customer sectors

Technology and innovation leadership to drive profitable growth

Strong R&D focus


- Approximately 1,900 employees in R&D around the globe.
- EUR ~338 million spent for R&D costs in 2025.*
- Very close collaboration with customers to develop new and improve existing products.
- Certified test-center at Lübeck headquarter supports innovation- and approval process.
- Quality management organization with ~250 employees.
- Technological competency and high-quality standards result in leading market positions and high barriers to entry.

Innovation to enhance future growth (examples)



Oxylog 300

High-performance turbine-driven transport ventilator with comprehensive functions for patient transport within and between hospitals.



Lung Protective Ventilation Analytics - Intensive Care

SDC-enabled cloud-based service to support clinical decisions in ventilation management by analyzing relevant data.



X-plore 8300

Smallest and lightest PAPR device in its class, offering maximum protection and comfort. Can be combined with headpieces, hoses, and carrying options.


* In the 2025 fiscal year, around one percent of R&D costs were capitalized at EUR 3.8 million (2024: 0.0%).

Exploit growth potentials in developing countries

Investments in profitable growth in developing countries

- Focus on the specific needs of customer in developing countries
- Capitalize on the significant investments into the Sales & Service infrastructure and specific market knowledge, especially in our Region Asia-Pacific and in Central- and South-America
- Enhance engagement with partners in developing countries to expand local presence with R&D, manufacturing, sales and after sales business

Net sales share*



Focused product range



Atlan A100



PSS 3200



HPS C100

* In fiscal year 2025
Drägerwerk AG & Co. KGaA

Service- and consumables business a clear focus of our sales activities

Further expansion of service and consumables business

- Capitalize on large installed base to expand after sales business
- Focus on combined sale of equipment and after sales contracts
- Expansion of disposable consumables business

Dräger Services

- Globally over 3,100 service technicians
- Fast and reliable service (repairs and spare parts) is a critical factor for customers
- Dräger Service technicians important for customer loyalty
- Efficient service solutions via remote service
- Broad offerings of product service
- New services in the areas of Rental, Multi-Vendor and Marine-offshore

Dräger Consumables

- Functionalities with added value, e.g. optimizing workflow with RFID-based communication between consumables part and therapy machine
- Dräger quality to improve hygienic standards
- Dräger value add especially in development of consumables. Production usually via suppliers
- Partly proprietary consumable products, e.g. Dräger tubes



02

—

Financials

Business development

Dräger Group – 5-year view

Dräger Group	2021	2022	2023	2024	2025	Q1 2026	Q1 2025
	€ million	€ million	€ million	€ million	€ million	€ million	€ million
Net sales	3,328	3,045	3,374	3,371	3,482	756	730
Change (nominal)	-2.3%	-8.5%	10.8%	-0.1%	3.3%	3.5%	-0.8%
Change (net of currency effects)	-1.8%	-11.5%	13.1%	0.5%	5.3%	6.9%	-1.2%
Gross margin	46.3%	40.7%	43.3%	44.9%	45.2%	46.3%	45.8%
Functional expenses	-1,264	-1,323	-1,287	-1,306	-1,346	-331	-334
% of net sales	-38.0%	-43.4%	-38.1%	-38.8%	-38.7%	-43.8%	-45.7%
EBIT	271.7	-88,6	166.4	194	233	17.9	0.4
EBIT margin	8.2%	-2.9%	4.9%	5.8%	6.7%	2.4%	0.1%
DVA	172	-196	56	54	90	106	39

Dräger Value Added (DVA) = EBIT less cost of capital of average invested capital

Key figures

Dräger Group – 5-year view

Dräger Group	2021	2022	2023	2024	2025	Q1 2026	Q1 2025	Change
	€ million	€ million	€ million	€ million	€ million	€ million	€ million	%
Cashflow (from operating activities)	385	-144	190	167	238	62	56	10.9
Investments	194	131	142	126	167	33	29	13.3
Cash and cash equivalents ¹	446	312	272	231	282	269	250	7.8
Net financial debt ¹	-24	259	198	165	123	85	142	-39.7
Net financial debt ¹ / EBITDA ²	-0.1	4.6	0.6	0.5	0.3	0.2	0.4	
Capital employed ¹	1,381	1,537	1,523	1,601	1,661	1,648	1,555	6.0
ROCE (EBIT ² / capital employed ¹)	19.7%	-5.8%	10.9%	12.1%	14.1%	15.2%	11.5%	
Net Working Capital ¹	517	661	659	741	755	745	697	6.9
Equity ratio	39.7	42.5	45.5	49.7	51.5	52.3	49.9	2.4pp
Headcount ¹	15,900	16,219	16,329	16,598	16,687	16,708	16,615	0.6

¹ Values as of reporting date

² EBITDA and accordingly EBIT of the last twelve months

03

—

Outlook

Outlook

Expectations for fiscal year 2026

Indicator	Results achieved for fiscal year 2025	Current forecast for fiscal year 2026
Net sales (net of currency effects)	5.3%	2.0 to 6.0%
EBIT margin	6.7%	5.0 to 7.5%
Dräger Value Added (DVA)	EUR 90.1 million	EUR 20 to 120 million

Outlook

Mid-term

Corporate Objectives

-
- Improve DVA
 - We will achieve a positive DVA in 2024 and also in all subsequent years.

01

Profitability first

Priority has changed from revenue growth towards profitability.

Shift from sales growth to earnings growth by

- Increasing profitability by exploiting opportunities, price enforcement and cost discipline
- Even stronger focus of activities on customer needs
- Consistent implementation of own initiatives
- Adjustment or discontinuation of unprofitable activities

-
- Increase in the EBIT margin by an average of 1 PP per year from 2024

02

Innovation Leadership

Revitalize our innovation, deploy this strength successfully to our markets and become first choice for our customers.

Revitalizing our innovation by

- Investing in the development of innovative products
- Investing in commercial innovation to develop business models that meet the needs of our existing and future customers
- Promoting local innovation and value creation in the countries, particularly in services, project business and add-on software, by offering customized solutions where they are used

-
- Increase innovation share

03

Competence in Interoperability/System Business

We enhance the level of competence on interoperability, system and solution business.

Concentration on the systems business with the aim to

- Increase the share of wallet (customer purchase potential)
- Increase the share of mind (brand loyalty)
- Even deeper integration into the customer's value creation process
- Stronger development of our transaction and part number-oriented business towards an approach based on system solutions and cash flow orientation

-
- Increase share of systems and solutions systems
 - Train sales and service employees
 - Increase maturity-level of key countries

Technology for Life



Dräger

Outlook

Expectations for fiscal year 2026

Indicator	Results achieved for fiscal year 2025	Forecast for fiscal year 2026
Net sales (net of currency effects)	5.3%	2.0 to 6.0%
EBIT margin	6.7%	5.0 to 7.5%
DVA	EUR 90.1 million	EUR 20 to 120 million
Gross margin	45.2%	44.0 to 46.0%
R&D costs ¹	EUR 337.6 million	EUR 335 to 355 million
Net financial debt	EUR 123.0 million	EUR 140 to 170 million
Investment volume ²	EUR 103.1 million	EUR 110 to 130 million
Net interest result	EUR -17.7 million	EUR -15 to -21 million
Days Working Capital (DWC)	105.8 days	104 to 109 days

Drägerwerk AG & Co. KGaA ¹ R&D expenses were forecast up to the 2025 fiscal year. From the 2026 fiscal year, R&D costs (including capitalized R&D costs) are forecast. ² Excluding company acquisitions, investments in financial assets, and the capitalization of right-of-use assets pursuant to IFRS 16

Management

The Dräger Executive Board



Stefan Dräger

Chairman of the Executive Board - The fifth generation of the Dräger family to lead the company

With Dräger since 1992



Gert-Hartwig Lescow

Deputy Chairman of the Executive Board; CFO and Executive Board member for IT

With Dräger since 2008



Stefanie Hirsch

Executive Board Member for Sustainability and Quality

With Dräger since 2018



Rainer Klug

Executive Board member for Safety Division

With Dräger since 2015



Dr. Reiner Piske

Executive Board member for Sales & Service and Human Resources

With Dräger since 2015




Anton Schrofner

Executive Board member for Medical Division

With Dräger since 2010

Dräger shares

Shareholder structure



¹ As of December 31, 2025
Drägerwerk AG & Co. KGaA

² Common shares (excluding Dräger family shares) and preferred shares; as at December 31, 2025

Business development

Group / Division / Region

Dräger Group	2022	2023	2024	2025	Q1 2026	Q1 2025	Change	Change
	€ million	€ million	€ million	€ million	€ million	€ million	% nominal	% fx-adj.
Medical division	1,821.5	1,966.2	1,899.7	1,995.6	417.7	413.1	1.1	5.4
Safety division	1,223.7	1,407.3	1,471.2	1,486.3	338.2	317.2	6.6	8.8
Total	3,045.2	3,373.5	3,370.9	3,481.9	755.9	730.3	3.5	6.9
Germany	665.5	748.4	775.8	804.3	185.1	176.6	4.8	4.8
EMEA	1,167.7	1,309.8	1,310.5	1,396.7	303.8	284.4	6.8	7.6
Americas	619.7	700.7	736.8	737.4	161.6	150.7	7.2	15.4
APAC	592.4	614.7	547.8	543.4	105.4	118.5	-11.1	-2.5
EBIT	40.7%	43.3%	44.9%	45.2%	46.3%	45.8%	0.5pp	
EBIT margin	-88.6	166.4	194.0	233.4	17.9	0.4	> +100	

Medical division

Business development

Medical division	2022	2023	2024	2025	Q1 2026	Q1 2025	Change	Change
	€ million	€ million	€ million	€ million	€ million	€ million	% nominal	% fx-adj.
Net sales	1,821.5	1,966.2	1,899.7	1,995.6	417.7	413.1	1.1	5.4
Germany	367.5	402.7	406.8	435.0	101.5	99.2	2.3	2.3
EMEA	645.9	699.8	678.6	733.4	146.8	143.2	2.5	4.1
Americas	412.3	454.2	474.1	493.3	101.8	94.7	7.6	15.6
APAC	395.9	409.4	340.2	333.9	67.5	76.0	-11.2	-0.7
EBIT	40.2%	41.9%	43.0%	43.6%	43.9%	42.1%	1.8pp	
EBIT margin	-90.4	37.1	28.3	57.0	-18.5	-27.7	33.2	

Note: The data, including the quarterly figures, can be downloaded from the Dräger website in .xls-format

Safety division

Business development

Safety division	2022	2023	2024	2025	Q1 2026	Q1 2025	Change	Change
	€ million	€ million	€ million	€ million	€ million	€ million	% nominal	% fx-adj.
Net sales	1,223.7	1,407.3	1,471.2	1,486.3	338.2	317.2	6.6	8.8
Germany	298.0	345.6	369.0	369.4	83.5	77.4	8.0	8.0
EMEA	521.8	609.9	631.9	663.3	157.0	141.3	11.1	11.1
Americas	207.4	246.6	262.7	244.1	59.7	56.0	6.6	15.0
APAC	196.5	205.2	207.6	209.5	37.9	42.5	-10.8	-5.6
EBIT	41.4%	45.2%	47.3%	47.3%	49.2%	50.6%	-1.4pp	
EBIT margin	1.8	129.4	165.7	176.4	36.4	28.2	29.4	

Note: The data, including the quarterly figures, can be downloaded from the Dräger website in .xls-format

Functional expenses

Dräger Group – 5-year view

Dräger Group	2021	2022	2023	2024	2025	Q1 2026	Q1 2025	Change
	€ million	€ million	€ million	€ million	€ million	€ million	€ million	%
R&D	328.6	343.5	325.4	333.1	333.8	79.8	83.6	-4.5
% of net sales	9.9%	11.3%	9.6%	9.9%	9.6%	10.6%	11.4%	
Sales & Marketing	672.9	717.9	717.8	731.8	729.5	181.6	180.1	0.8
% of net sales	20.2%	23.6%	21.3%	21.7%	21.0%	24.0%	24.7%	
Administration	261.1	258.7	237.9	275.9	285.0	68.8	69.6	-1.2
% of net sales	7.8%	8.5%	7.1%	8.2%	8.2%	9.1%	9.5%	
Other operating income	1.1	3.0	5.8	-34.4	-2.1	0.7	0.4	92.9
Functional expenses total	1,263.7	1,323.0	1,286.9	1,306.4	1,346.3	331.0	333.7	-0.8
% of net sales	38.0%	43.4%	38.1%	38.8%	38.7%	43.8%	45.7%	
Headcount ¹	15,900	16,219	16,329	16,598	16,687	16,708	16,615	0.6

¹ Values as of reporting date

Cash flow statement

Dräger Group – 5-year view

Dräger Group	2021	2022	2023	2024	2025	Q1 2026	Q1 2025	Change
	€ million	€ million	€ million	€ million	€ million	€ million	€ million	%
Group net profit	154.3	-63.6	112.0	124.8	140.4	11.3	-1.9	>+100
Change in inventories	14.4	-81.8	13.0	-6.2	2.9	-66.2	-60.3	-9.8
Change in receivables	122.3	-74.7	-68.5	-67.9	-66.1	98.5	116.8	-15.6
Change in payables	-15.8	66.3	-67.2	14.9	8.9	-0.9	-17.5	94.6
Depreciation and amortization	148.3	141.9	151.3	147.0	136.3	31.9	32.9	-3.1
Other operating cash flow items	-38.6	-132.3	49.1	-45.3	16.1	-12.5	-14.1	11.0
Operating cash flow	384.9	-144.2	189.7	167.3	238.3	62.0	55.9	10.9
Investing cash flow ³	-109.9	36.8	-67.3	-43.4	-98.1	-17.9	-23.9	25.0
Free cash flow	275.0	-107.4	122.3	123.9	140.2	44.1	32.0	37.8
Financing cash flow	-334.6	-29.4	-154.6	-161.4	-84.0	-59.0	-12.1	>-100
Change in cash ¹	-59.7	-136.8	-32.2	-37.5	56.2	-14.9	19.9	>-100
Cash and cash equivalents ²	445.7	311.6	272.0	230.6	282.1	269.1	249.6	7.8

¹ Change in cash and cash equivalents, i.e. without any effect of exchange rates; ² Value as of reporting date; ³ Incl. short-term, highly liquid money market funds

Balance sheet (assets)

Group 12M

Assets	12.2025	12.2024	Change
	€ million	€ million	%
Intangible assets	336.2	342.8	-1.9
Property, plant and equipment (incl. Right-of-use-assets)	559.5	549.0	1.9
Other noncurrent assets	352.9	316.8	11.4
Noncurrent assets	1,248.5	1,208.7	3.3
Inventories	629.0	662.6	-5.1
Trade receivables	807.6	788.4	2.4
Other current assets	195.8	203.1	-3.6
Cash and cash equivalents	282.1	230.6	22.3
Current assets	1,914.6	1,884.8	1.6
Total assets	3,163.1	3,093.4	2.3

Balance sheet (equity and liabilities)


Group 12M

Equity and liabilities	12.2025	12.2024	Change
	€ million	€ million	%
Equity	1,628.7	1,536.8	6.0
Provisions for pensions and similar obligations	152.2	180.4	-15.6
Noncurrent personnel provisions	37.6	36.6	2.8
Noncurrent interest bearing loans	153.7	104.4	47.3
Noncurrent note loans	50.0	100.0	-50.0
Other noncurrent liabilities	196.5	156.8	25.3
Noncurrent liabilities	590.0	578.2	2.1
Current provisions	200.5	266.5	-24.8
Current loans	50.0	-	+100
Current loans and liabilities to banks	18.7	67.4	-72.3
Trade payables	282.1	230.6	22.3
Other current liabilities	393.2	413.9	-5.0
Current liabilities	944.4	978.5	-3.5
Total equity and liabilities	3,163.1	3,093.4	2.3

Business development Dräger Group – 5 years


Order intake¹

fx-adj.	-17.9%	+2.9%	+2.2%	+3.4%	+7.7%
nominal	-18.4%	+6.4%	+0.2%	+2.8%	+5.6%




Net sales¹

-1.8%	-11.5%	+13.1%	+0.5%	+5.3%
-2.3%	-8.5%	+10.8%	-0.1%	+3.3%



EBIT¹ (margin)

(8.2%)	(-2.9%)	(4.9%)	(5.8%)	(6.7%)
--------	---------	--------	--------	--------




¹ in EUR million

Drägerwerk AG & Co. KGaA

Business development Dräger Group – 5 years


DVA¹



¹ in EUR million


Equity¹ (ratio)

(39.7%) (42.5%) (45.5%) (49.7%) (51.5%)



Net financial debt¹ (/EBITDA)

(-0.06) (4.64) (0.63) (0.49) (0.33)




Business development

Medical division – 5 years


Order intake¹

	2021	2022	2023	2024	2025
fx-adj.	-22.6%	-0.5%	-1.3%	+1.2%	+8.9%
nominal	-23.3%	+3.3%	-3.2%	+0.4%	+6.4%




Net sales¹

	2021	2022	2023	2024	2025
fx-adj.	-9.7%	-15.0%	+10.3%	-2.7%	7.4%
nominal	-10.3%	-11.8%	+7.9%	-3.4%	5.0%



EBIT¹ (margin)

	2021	2022	2023	2024	2025
fx-adj.	(9.3%)	(-5.0%)	(1.9%)	(1.5%)	(2.9%)




¹ in EUR million

Business development

Safety division – 5 years


Order intake¹

fx-adj.	-8.8%	+8.4%	+7.4%	+6.4%	+6.1%
nominal	-9.1%	+11.5%	+5.2%	+6.0%	+4.6%




Net sales¹

+14.5%	-5.8%	+17.2%	+4.9%	+2.6%
+14.5%	-3.2%	+15.0%	+4.5%	+1.0%



EBIT¹ (margin)

(6.3%)	(0.1%)	(9.2%)	(11.3%)	(11.9%)
--------	--------	--------	---------	---------




¹ in EUR million


Dividend policy

Dräger intends to continue distributing at least 30% of consolidated annual net profit in the coming years, provided that the Group's equity ratio is at least 40%.


Total distribution¹ (rate)



Dividend (yield) per common share²








Dividend (yield) per preferred share²



¹ in EUR thousand, including distribution to participation certificate holders (less taxes and minimum dividends); 2025 distribution subject to the approval of the annual shareholders' meeting; ² in EUR thousand Drägerwerk AG & Co. KGaA

Sustainability Ratings

Rating agency	Overall rating	Further information
 ecovadis	73 out of 100 points (silver medal)	Dräger is among the top 15 % of the companies assessed by Ecovadis.
 ISS ESG	C+ on a scale from AAA (Leader) to CCC (Laggard) 56.67 points (Prime Status) on a scale from ≥50 (Prime) to <50 (Not Prime)	Dräger has a “very high” transparency level.
 SUSTAINALYTICS	26.5 points (medium risk) on a scale from 0 - 10 (negligible risk) to 40+ (severe risk)	Dräger is ranked 61st out of 217 in the “Medical Devices” sector.
 CDP	C (in the areas of “Climate Change” and “Water Security”) on a scale from A (Leadership Level) to F (no response or declined to participate)	The “Forests” area was not evaluated.
 MSCI	A on a scale from AAA (Leader) to CCC (Laggard)	With its A rating, Dräger occupies a top position in the “Health Care Equipment & Supplies” sector.

Sustainability Ratings

- Dräger improved slightly to 73 out of 100 points (2024: 72 points) in the CSR assessment carried out by the EcoVadis institute in 2025, again securing a Silver Medal. This puts Dräger among the best 15% of companies assessed by EcoVadis.
- In addition, Dräger retained the “Prime Label” in ISS’ ESG Corporate Rating, taking a top position in the “Health Care Equipment & Suppliers” sector.
- U.S. financial services provider MSCI awarded Dräger an ESG rating of A on a scale of AAA (leader) to CCC (laggard).
- Sustainalytics, the sustainability rating agency, gave Dräger an ESG risk rating of “Medium Risk”. This puts Dräger in the top 30% of companies in the “Medical Devices” sector.
- Furthermore, the Carbon Disclosure Project (CDP) non-profit organization confirmed out C rating (on a scale from A to D-). The areas assessed were water and climate.
- Incorporation of ESG criteria in corporate financing (promissory note loans, master loan agreement)



ascom

B BRAUN

Dräger

Muting and forwarding alarms

Analgesia control

Gentle ventilation and weaning

Patient monitoring



Silent ICU

- Concept for alarm forwarding and muting of medical devices with Service-oriented Device Connectivity (SDC)
- Information flows bi-directionally across manufacturers with SDC
- Patient devices remain muted – alarms are sent to staff in a targeted manner

Financial calendar

Events

Dräger publishes preliminary results approximately 2 weeks before the dates of the quarterly reports. Preliminary results for the full year are published in January.

March 24, 2026	Annual Report 2025 Conference Call
April 30, 2026	Report for the first three months 2026 Conference Call
May 8, 2026	Annual shareholders' meeting 2026 Lübeck, Germany
July 30, 2026	Report for the first six months 2026 Conference Call
October 29, 2026	Report for the first nine months 2026 Conference Call

Contact

Visit our Investor Relations website:
https://www.draeger.com/en-us_us/Investor-Relations



Thomas Fischler | Head of Treasury & Investor Relations

Moislinger Alle 53-55
23558 Lübeck, Germany
Tel. +49 451 882 2685
Mail: thomas.fischler@draeger.com

Nikolaus Hammerschmidt | Investor Relations Manager

Moislinger Alle 53-55
23558 Lübeck, Germany
Tel. +49 451 882 8903
Mail: nikolaus.hammerschmidt@draeger.com



Thank you